Nanoemulsion nasal adjuvant W805EC induces dendritic cell engulfment of antigen-primed epithelial cells

Vaccine

Volumn 31, Issue 7, 2013, Pages 1072-1079

  Myc, Andrzej ^a,b   Kukowska Latallo, Jolanta F ^a   Smith, Douglas M ^a   Passmore, Crystal ^a   Pham, Tiffany ^a   Wong, Pamela ^a   Bielinska, Anna U ^a   Baker, James R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Antibodies; Antigens; Cytokines; Immunization

Indexed keywords

CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN G2C ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMORAL IMMUNITY; IMMUNITY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NANOEMULSION; NONHUMAN; NOSE MUCOSA; PHAGOCYTOSIS; PRIORITY JOURNAL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; DENDRITIC CELLS; EMULSIONS; EPITHELIAL CELLS; FEMALE; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS;

EID: 84872616886     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.033     Document Type: Article

References (55)

1. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
2. De Gregorio E., Tritto E., Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 2008, 38(8):2068-2071.
3. Gupta R.K., Siber G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995, 13(14):1263-1276.
4. Skowronski D.M., Janjua N.Z., De Serres G., Hottes T.S., Dickinson J.A., Crowcroft N., et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011, 342:c7297.
5. Gupta R.K., Rost B.E., Relyveld E., Siber G.R. Vaccine design: the subunit and vaccine approach 1995, Plenum, New York.
6. Wijburg O.L., Van Den Dobbelsteen G.P., Vadolas J., Sanders A., Strugnell R.A., Van Rooijen N. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur J Immunol 1998, 28(2):479-487.
7. Vajdy M., Srivastava I., Polo J., Donnelly J., O'Hagan D., Singh M. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 2004, 82(6):617-627.
8. Martinon F., Krishnan S., Lenzen G., Magne R., Gomard E., Guillet J.G., et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 1993, 23(7):1719-1722.
9. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239:178-196.
10. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11(Suppl. 4):S63-S68.
11. Weck M.M., Grunebach F., Werth D., Sinzger C., Bringmann A., Brossart P. TLR ligands differentially affect uptake and presentation of cellular antigens. Blood 2007, 109(9):3890-3894.
12. Zhu Q., Egelston C., Gagnon S., Sui Y.J., Belyakov I.M., Klinman D.M. Berzofsky JA: using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010, 120(2):607-616.
13. Bernasconi N.L., Onai N., Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003, 101(11):4500-4504.
14. Watts C., Zaru R., Prescott A.R., Wallin R.P., West M.A. Proximal effects of Toll-like receptor activation in dendritic cells. Curr Opin Immunol 2007, 19(1):73-78.
15. Liang S.A., Hajishengallis G. Heat-labile;1; enterotoxins as adjuvants or anti-inflammatory agents. Immunol Invest 2010, 39(4-5):449-467.
16. Hajishengallis G., Arce S., Gockel C.M., Connell T.D., Russell M.W. Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections. J Dent Res 2005, 84(12):1104-1116.
17. Hamouda T., Baker J.R. Antimicrobial mechanism of action of surfactant lipid preparations in enteric Gram-negative bacilli. J Appl Microbiol 2000, 89(3):397-403.
18. Hamouda T., Hayes M.M., Cao Z., Tonda R., Johnson K., Wright D.C., et al. A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. J Infect Dis 1999, 180(6):1939-1949.
19. Hamouda T., Myc A., Donovan B., Shih A.Y., Reuter J.D., Baker J.R. A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. Microbiol Res 2001, 156(1):1-7.
20. LiPuma J.J., Rathinavelu S., Foster B.K., Keoleian J.C., Makidon P.E., Kalikin L.M., et al. In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob Agents Chemother 2009, 53(1):249-255.
21. Myc A., Vanhecke T., Landers J.J., Hamouda T., Baker J.R. The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi. Mycopathologia 2002, 155(4):195-201.
22. Bielinska A.U., Janczak K.W., Landers J.J., Makidon P., Sower L.E., Peterson J.W., et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007, 75(8):4020-4029.
23. Bielinska A.U., Janczak K.W., Landers J.J., Markovitz D.M., Montefiori D.C., Baker J.R. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008, 24(2):271-281.
24. Makidon P.E., Bielinska A.U., Nigavekar S.S., Janczak K.W., Knowlton J., Scott A.J., et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE 2008, 3(8):e2954.
25. Makidon P.E., Knowlton J., Groom J.V., 2nd, Blanco L.P., LiPuma J.J., et al. Induction of immune response to the 17kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med Microbiol Immunol 2010, 199(2):81-92.
26. Bielinska A.U., Chepurnov A.A., Landers J.J., Janczak K.W., Chepurnova T.S., Luker G.D., et al. A novel, killed-virus nasal vaccinia virus vaccine. Clin Vaccine Immunol 2008, 15(2):348-358.
27. Hamouda T., Chepurnov A., Mank N., Knowlton J., Chepurnova T., Myc A., et al. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin 2010, 6(7):585-594.
28. Lindell D.M., Morris S.B., White M.P., Kallal L.E., Lundy P.K., Hamouda T., et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS ONE 2011, 6(7):e21823.
29. Myc A., Kukowska-Latallo J.F., Bielinska A.U., Cao P., Myc P.P., Janczak K., et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 2003, 21(25/26):3801-3814.
30. Bielinska A.U., Gerber M., Blanco L.P., Makidon P.E., Janczak K.W., Beer M., et al. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit Rev Immunol 2010, 30(2):189-199.
31. 805EC combined with approved seasonal influenza antigens. Vaccine 2012, 30(2):307-316.
32. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992, 176(6):1693-1702.
33. Jouvin-Marche E., Morgado M.G., Leguern C., Voegtle D., Bonhomme F., Cazenave P.A. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes. Immunogenetics 1989, 29(2):92-97.
34. Martin R.M., Lew AM Is IgG2a a good Th1 marker in mice?. Immunol Today 1998, 19(1):49.
35. Martin R.M., Brady J.L., Lew A.M. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 1998, 212(2):187-192.
36. Brouckaert G., Kalai M., Krysko D.V., Saelens X., Vercammen D., Ndlovu M., et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell 2004, 15(3):1089-1100.
37. Hanayama R., Tanaka M., Miwa K., Shinohara A., Iwamatsu A., Nagata S. Identification of a factor that links apoptotic cells to phagocytes. Nature 2002, 417(6885):182-187.
38. Levine M.M., Sztein M.B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 2004, 5(5):460-464.
39. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
40. Makidon P.E., Belyakov I.M., Janczak K.W., Lenders J., Bielinska A.U., Groom J.V., et al. Nanoemulsion mucosal adjuvant uniquely activates cytokine production be nasal ciliated epithelium and induces dendritic cells trafficking. Eur J Immunol 2012, 42(8):2073-2086.
41. Shen S.S., Yang Y.W. Antigen delivery for cross priming via the emulsion vaccine adjuvants. Vaccine 2012, 30(9):1560-1571.
42. Lanzavecchia A., Lezzi G. Viola A: from TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell 1999, 96(1):1-4.
43. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996, 14:233-258.
44. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat Rev Immunol 2002, 2(2):116-126.
45. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392(6671):86-89.
46. Albert M.L., Pearce S.F., Francisco L.M., Sauter B., Roy P., Silverstein R.L., et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998, 188(7):1359-1368.
47. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000, 191(3):423-434.
48. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002, 20:621-667.
49. Iyoda T., Shimoyama S., Liu K., Omatsu Y., Akiyama Y., Maeda Y., et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002, 195(10):1289-1302.
50. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999, 5(11):1249-1255.
51. Lohmann C., Muschaweckh A., Kirschnek S., Jennen L., Wagner H., Hacker G. Induction of tumor cell apoptosis or necrosis by conditional expression of cell death proteins: analysis of cell death pathways and in vitro immune stimulatory potential. J Immunol 2009, 182(8):4538-4546.
52. Lecoeur H., Prevost M.C., Gougeon M.L. Oncosis is associated with exposure of phosphatidylserine residues on the outside layer of the plasma membrane: a reconsideration of the specificity of the annexin V/propidium iodide assay. Cytometry 2001, 44(1):65-72.
53. Yang Y.W., Wu C.A., Morrow W.J. The apoptotic and necrotic effects of tomatine adjuvant. Vaccine 2004, 22(17/18):2316-2327.
54. Yang Y.W., Wu C.A., Morrow W.J. Cell death induced by vaccine adjuvants containing surfactants. Vaccine 2004, 22(11-12):1524-1536.
55. Yang Y.W., Shen S.S. Enhanced antigen delivery via cell death induced by the vaccine adjuvants. Vaccine 2007, 25(45):7763-7772.